Effects of Livagen peptide on chromatin activation in lymphocytes from old people.
Khavinson. V Kh VKh; Lezhava. T A TA; Monaselidze. J G JG; Dzhokhadze. T A TA; Dvalishvili. N A NA; Bablishvili. N K NK; Ryadnova. I Yu IY
Key Findings
- Livagen activates ribosomal gene activity in old lymphocytes
- It decondenses pericentromeric heterochromatin, loosening DNA structure
- It re‑activates genes that are normally repressed in aging cells
Practical Outcomes
- Livagen shows a cellular effect that might support anti‑aging processes, but the research is limited to lab cells and provides no dosage or safety info for humans. For now, it’s an interesting mechanistic clue rather than a ready‑to‑use protocol for biohackers.
Summary
The study found that the synthetic peptide Livagen can change the way DNA is packaged in white blood cells from older people, making certain genes more active. It seems to loosen tightly packed DNA regions and turn on genes that usually get turned off with age, which could be linked to healthier cells.
Abstract
We studied the effects of the synthetic peptide Livagen on activity of ribosomal genes, denaturation parameters of heterochromatin, polymorphism of structural C-heterochromatin, and variability of facultative heterochromatin in lymphocytes from old people. Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in chromosomes. Our results indicate that Livagen causes de-heterochromatinization (activation) of chromatin, which is realized via modification of heterochromatin and heterochromatinized regions in chromosomes from old people.
Study Information
pubmed
2002
10.1023/a:1021924702103